ImmuPharma

ImmuPharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of ImmuPharma (IMM.L) as of Nov 22, 2026 is -19.17. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -26.27 — a change of -27.02% (higher).

EV/FCF

-19.17

YoY

-27.02%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of ImmuPharma is 2025 -19.17 . EV/FCF (Enterprise Value to Free Cash Flow) of ImmuPharma was 2024 -26.27 . It decreases by -27.02% higher compared to the previous year.

The ImmuPharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-8.70 GBP
Jan 1, 2019
-10.49 GBP
Jan 1, 2020
-11.26 GBP
Jan 1, 2021
-9.23 GBP
Jan 1, 2022
-18.79 GBP
Jan 1, 2023
-34.11 GBP
Jan 1, 2024
-26.27 GBP
Jan 1, 2025
-19.17 GBP
The ImmuPharma EV/FCF history
YEAREV/FCFYoY
-19.17-27.02%
-26.27-22.99%
-34.11+81.58%
-18.79+103.43%
-9.23-17.96%
-11.26+7.29%
-10.49+20.62%
-8.70-12.66%
-9.96+42.89%
-6.97-37.33%
-11.12-25.06%
-14.84—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuPharma Stock analysis

What does ImmuPharma do? ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuPharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of ImmuPharma is -19.17 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of ImmuPharma changed from -26.27 to -19.17, representing a -27.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) ImmuPharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s ImmuPharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ImmuPharma

All Key Metrics — ImmuPharma